These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 15205878)

  • 1. Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists.
    Friedman JI
    Psychopharmacology (Berl); 2004 Jun; 174(1):45-53. PubMed ID: 15205878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapy of cognitive deficits in schizophrenia with acetylcholinesterase inhibitors. A systematic overview].
    Voss B; Thienel R; Leucht S; Kircher T
    Nervenarzt; 2008 Jan; 79(1):47-8, 50-2, 54-9. PubMed ID: 17960354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Muscarinic agonists for the treatment of cognition in schizophrenia.
    Sellin AK; Shad M; Tamminga C
    CNS Spectr; 2008 Nov; 13(11):985-96. PubMed ID: 19037177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial.
    Keefe RS; Malhotra AK; Meltzer HY; Kane JM; Buchanan RW; Murthy A; Sovel M; Li C; Goldman R
    Neuropsychopharmacology; 2008 May; 33(6):1217-28. PubMed ID: 17625502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological aspects of the acetylcholinesterase inhibitor galantamine.
    Ago Y; Koda K; Takuma K; Matsuda T
    J Pharmacol Sci; 2011; 116(1):6-17. PubMed ID: 21498956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of the cholinesterase inhibitors in the treatment of schizophrenia.
    Pae CU
    Expert Opin Investig Drugs; 2013 Mar; 22(3):293-8. PubMed ID: 23330829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literature.
    Ribeiz SR; Bassitt DP; Arrais JA; Avila R; Steffens DC; Bottino CM
    CNS Drugs; 2010 Apr; 24(4):303-17. PubMed ID: 20297855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacological profiles of galantamine: the involvement of muscarinic receptor].
    Matsuda T; Ago Y; Takuma K
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2012 Feb; 32(1):1-8. PubMed ID: 22568120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of adjunct galantamine to risperidone, or haloperidol, in animal models of antipsychotic activity and extrapyramidal side-effect liability: involvement of the cholinergic muscarinic receptor.
    Wadenberg ML; Fjällström AK; Federley M; Persson P; Stenqvist P
    Int J Neuropsychopharmacol; 2011 Jun; 14(5):644-54. PubMed ID: 20701827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Muscarinic agonists and antagonists in schizophrenia: recent therapeutic advances and future directions.
    Bolbecker AR; Shekhar A
    Handb Exp Pharmacol; 2012; (208):167-90. PubMed ID: 22222699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treating schizophrenia: novel targets for the cholinergic system.
    Money TT; Scarr E; Udawela M; Gibbons AS; Jeon WJ; Seo MS; Dean B
    CNS Neurol Disord Drug Targets; 2010 Apr; 9(2):241-56. PubMed ID: 20053170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy.
    Ferreri F; Agbokou C; Gauthier S
    J Psychiatry Neurosci; 2006 Nov; 31(6):369-76. PubMed ID: 17136214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic potential of TAK-071, a muscarinic M
    Kurimoto E; Yamada R; Hirakawa T; Kimura H
    Neurosci Lett; 2021 Nov; 764():136240. PubMed ID: 34509568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New pharmacological approaches to the cholinergic system: an overview on muscarinic receptor ligands and cholinesterase inhibitors.
    Greig NH; Reale M; Tata AM
    Recent Pat CNS Drug Discov; 2013 Aug; 8(2):123-41. PubMed ID: 23597304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Muscarinic mechanisms in psychotic disorders.
    McKinzie DL; Bymaster FP
    Handb Exp Pharmacol; 2012; (213):233-65. PubMed ID: 23027418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective activation of muscarinic acetylcholine receptors for the treatment of schizophrenia.
    Dean B
    Curr Pharm Biotechnol; 2012 Jun; 13(8):1563-71. PubMed ID: 22283751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease.
    Fisher A
    Neurotherapeutics; 2008 Jul; 5(3):433-42. PubMed ID: 18625455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel M(1) allosteric ligands: a patent review.
    Kuduk SD; Beshore DC
    Expert Opin Ther Pat; 2012 Dec; 22(12):1385-98. PubMed ID: 23092292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Donepezil and the alpha-7 agonist PHA 568487, but not risperidone, ameliorate spatial memory deficits in a subchronic MK-801 mouse model of cognitive impairment in schizophrenia.
    Karamihalev S; Prickaerts J; van Goethem NP
    Behav Brain Res; 2014 Oct; 272():248-51. PubMed ID: 25036424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cognitive effects of adjunctive 24-weeks Rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind investigation.
    Sharma T; Reed C; Aasen I; Kumari V
    Schizophr Res; 2006 Jul; 85(1-3):73-83. PubMed ID: 16797163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.